Search results
Results from the WOW.Com Content Network
Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8 + T cells and NK cells.
The composition of monocyte-derived macrophages and tissue-resident macrophages in the tumor microenvironment depends on the tumor type, stage, size, and location, thus it has been proposed that TAM identity and heterogeneity is the outcome of interactions between tumor-derived, tissue-specific, and developmental signals. [2]
[1] [2] [3] The compound was developed as a successor of previous drugs in the EPI series such as EPI-001, ralaniten (EPI-002), and ralaniten acetate (EPI-506). [ 1 ] [ 2 ] [ 3 ] Masofaniten shows 20-fold higher antiandrogenic potency than ralaniten in vitro ( IC 50 Tooltip Half-maximal inhibitory concentration = 535 nM vs. 9,580 nM ...
The company will not initiate the NEXI-003 trial in HPV-mediated tumors at this time, and, as previo NexImmune Shifts Focus On AIM Direct Injection Platform, Potential Candidates In Oncology ...
Phase II clinical trial The Phase II clinical trial was expected to begin in 2018 [ 8 ] in the United States to measure immune responses. The researchers planned to recruit about 600 HIV-negative volunteers who are in the high risk category for HIV infections such as commercial sex workers, men who have sex with men (MSM), injecting drug users ...
A monoclonal antibody targeting AXL (YW327.6S2) and an AXL decoy receptor (GL2I.T) are currently in preclinical development. Additionally, an oral AXL inhibitor (TP-0903) is expected to enter Phase 1 clinical trial in November 2016 (in advanced solid tumours: NCT02729298).
The legal team behind Mike Jeffries, arrested earlier this year on sex trafficking charges, has requested a hearing to determine his fitness to stand trial. Ex-Abercrombie & Fitch CEO has dementia ...
EPI-001's successor, ralaniten acetate (EPI-506), a prodrug of ralaniten (EPI-002), one of the four stereoisomers of EPI-001, was under clinical investigation in a phase I study. [3] EPI-506 was the first drug that directly binds to an intrinsically disordered region to be tested in humans and marks a leap in drug development from folded drug ...